Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

Impact on States of the Medicare Drug Benefit: Information for State Legislators

The new drug benefit established by Part D of the Medicare Modernization Act assures that all older and disabled persons have access to affordable prescription drug coverage and will subsidize many low-income persons who previously had no access to drug benefits through Medicaid or state pharmaceutical assistance programs. States have numerous policy decisions to make in implementing the Part D drug benefit, including several options to enhance the Part D program. These decisions must be made quickly in order to be ready for the January 1, 2006, implementation date. As the safety net provider for many vulnerable individuals, the state's choices on these matters are important to the future well-being of the elderly and disabled.

Newsletter Volume

E.V.I.dently June 2015

NPC MessageDriving Health System Value Through Broader Access to DataFrom Fitbits to insurance claims databases, we capture an enormous amount of...
Blog Post

Medicare Part D – A Beacon or a Warning Light?

The Medicare Part D prescription drug program has by nearly every measure been a success, but there is room for improvement, particularly when it...
Press Release

NPC Comments on CMS’ Announcement to Allow Broader Access to Publicly Funded Databases

(Washington, DC, June 2, 2015)—The National Pharmaceutical Council (NPC) today commented on the Centers for Medicare and Medicaid Services’ (CMS)...
Newsletter Volume

E.V.I.dently April 2015

MessageThe Health Care Paradigm Shift: Moving From Volume to ValueAs our health care payment and delivery systems shift from volume-based to...
Press Release

NPC Comments on CMS’ Announcement to Allow Broader Access to Publicly Funded Databases

(Washington, DC, June 2, 2015)—The National Pharmaceutical Council (NPC) today commented on the Centers for Medicare and Medicaid Services’ (CMS)...
Press Release

State Medicaid Directors Share Views on Comparative Effectiveness Research And Its Impact on Policy in National Pharmaceutical Council Survey

(Washington, DC, April 16, 2015)—A new survey conducted on behalf of the National Pharmaceutical Council (NPC) shows that state Medicaid directors...
Press Release

Study Quantifies Impact of Pharmaceuticals on Enhanced Productivity

(WASHINGTON, DC, August 1, 2012)–The costs to employers of chronic health conditions on employee productivity are well documented, but few studies...
Press Release

NPC Conference to Address Questions on Ability to Share Health Research Findings Health

(Washington, DC, February 6, 2012)--To examine key issues around asymmetries, or inequalities, in communicating health information coming from the...
Commentary and Testimony Page

NPC Comments on CMS' Proposed Changes to Protected Classes

March 7, 2014Marilyn B. TavennerAdministratorCenters for Medicare & Medicaid ServicesU.S. Department of Health and Human Services200 Independence...
Commentary and Testimony Page

Framework Helps ACOs Leverage Pharmaceuticals to Realize Quality, Cost Goals

Medications are more than an item on the balance sheet for health care providers. Pharmaceuticals offer a route to manage costs while achieving...
Commentary and Testimony Page

Asymmetry in the Ability to Communicate CER Findings: Ethics and Issues for Informed Decision Making

The number of voices in the comparative effectiveness research (CER) conversation is continuing to grow, but not all stakeholders have the same...
Commentary and Testimony Page

CER Done Right: Why It Matters

The health care reform law is aimed at reshaping the health care landscape through the creation of many new regulations and regulatory...
YouTube Videos

Can We Bring Clarity, Consistency and Transparency to Payer Coverage Decisions?

There is a bit of a "black box" around the formulary decision-making process. As a result, decisions about treatment access are often unpredictable...
YouTube Videos

How Do Payers Consider Individual Treatment Effects?

Dr. Robert Epstein, former chief medical officer and senior vice president of medical affairs at Medco Health, explains that heterogeneity, or...
YouTube Videos

AEI's Gottlieb on Ability to Communicate CER Findings

American Enterprise Institute's Dr. Scott Gottlieb discusses legal and regulatory challenges facing various health care stakeholders in their...
YouTube Videos

The Challenges of Finding, Using Accurate Health Care & CER Information

Dr. Art Caplan, Director of the Center for Bioethics at the University of Pennsylvania, explains that it can be challenging for patients to find...
Blog Post

Medicare Part D – A Beacon or a Warning Light?

The Medicare Part D prescription drug program has by nearly every measure been a success, but there is room for improvement, particularly when it...
Blog Post

#TBT: March is National Kidney Month

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...
Blog Post

Assessing the Value of Drugs for Formulary Decisions

Some of the National Pharmaceutical Council's (NPC) research partners participated today on a panel, "Best Practices for Assessing the Value of Drugs...
Blog Post

#TBT: Senior Citizens Day & Individualized Pharmaceutical Care

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...

Transparency in Evidence Evaluation and Formulary Decision-Making

Although the type of evidence required to make healt

2013 Comparative Effectiveness Research and the Environment for Health Care Decision-Making

2013 Comparative Effectiveness Research and the Environment for Health Care Decision-Making

NPC's 2013 survey shows that health care stakeholders have growing expectations for the use of...
  •  
  • 1 of 40
  • >